
USD
( +0.00%
At Close (As of Jan 1, 1970)
$313.33M
Market Cap
-
P/E Ratio
-2.07
EPS
$2.59
52 Week High
$0.53
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Total Assets | $11M |
| Total Current Assets | $10M |
| Cash And Cash Equivalents At Carrying Value | $9.8M |
| Cash And Short Term Investments | $9.8M |
| Inventory | $12K |
| Current Net Receivables | $24K |
| Total Non Current Assets | $386K |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $649K |
| Other Non Current Assets | - |
| Total Liabilities | $3.4M |
| Total Current Liabilities | $3.2M |
| Current Accounts Payable | $1.1M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $169K |
| Total Non Current Liabilities | $152K |
| Capital Lease Obligations | $90K |
| Long Term Debt | - |
| Current Long Term Debt | $79K |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $169K |
| Other Current Liabilities | $2M |
| Other Non Current Liabilities | $150K |
| Total Shareholder Equity | $7.5M |
| Treasury Stock | - |
| Retained Earnings | -$136M |
| Common Stock | $27K |
| Common Stock Shares Outstanding | $1.4M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Palisade Bio Inc. is a clinical-stage biopharmaceutical company headquartered in Carlsbad, California, dedicated to pioneering innovative therapies that protect the gastrointestinal mucosal barrier. The company focuses on developing proprietary drug candidates that tackle significant unmet needs in gastrointestinal disorders, reflecting its commitment to improving patient outcomes. With a robust emphasis on research and development, Palisade Bio is ideally positioned to enhance gastrointestinal health and drive transformative changes in treatment protocols within this vital therapeutic area. Through strategic initiatives, the company aims to deliver meaningful advancements in patient care and therapeutic effectiveness.